Sanjivani Paranteral Ltd
Sanjivani Paranteral Q1 FY27 investor presentation: Revenue & Margins
Q1 FY27 investor presentation: what the company reported on revenue, margins and projects.
Based on Sanjivani Paranteral Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Q1 FY27 Consolidated EBITDA: ₹43.21 Mn, up 61.04% YoY from ₹26.83 Mn - Q1 FY27 EBITDA margin: 18.01% (0.18 on total income), improvement from 15% in Q1 FY26 - Q1 FY27 Consolidated Profit After Tax
From Sanjivani Paranteral Ltd's Q1 FY27 earnings-call transcript · updated 10 Oct 2026.
Revenue & Sales Performance
- Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25).
- Q1 FY27 EBITDA: ₹43.21 Mn, up 61.0% YoY from ₹26.83 Mn in Q1 FY26 (Page 25).
- Q1 FY27 PAT: ₹24.91 Mn, up 43.9% YoY from ₹17.31 Mn in Q1 FY26 (Page 25).
- Export share in Q1 FY26 was 90.5% of revenue (₹176.10 Mn) (Page 28).
- Management expects FY27 revenue ~₹1,450 Mn across verticals: base business ₹800–850 Mn and IV fluid business ₹600–650 Mn (Page 35 & 17).
- IV fluid plant utilization guided to ramp from 40% to ~70% across FY27 (Page 36 & 11).
2 more points management made on revenue & sales performance
Profitability & Margins
See what Sanjivani Paranteral Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Pune IV-fluid infusion plant:
- Commercial production started Dec 2025
- Installed capacity: 60 million bottles/year
- Revenue ₹35 Mn in FY26 (~2 Mn bottles)
- Utilisation ramp guided from 40% in Q1 FY27 to 70% by FY27 end
- EBITDA margin target 17–18%, breakeven expected in FY27 as depreciation and interest normalize
- Prague nutraceutical JV:
- 45% stake
- Commercial batches started in 2025
- Capex phase completed with fixed assets doubling to ₹469 Mn (consolidated)
- FY27 is the beginning of the revenue phase post-capex
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sanjivani Paranteral Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Sanjivani Paranteral Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹11 Cr, net profit ₹1 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sanjivani Paranteral Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Symbiotec Pharma (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹218.2 crores, up 7% YoY from ₹203.2 crores in Q1 FY26 (Page 9). Key concall takeaways from Symbiotec Pharmalab…
- Jubilant Pharmova Ltd (Q1 FY27)
2,229 Cr., up 17% YoY (Page 97) . Key concall takeaways from Jubilant Pharmova Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.
- Beta Drugs Ltd (Q1 FY27)
Q1-FY27 revenue from operations: INR 1,255 Mn, up 25.2% YoY from INR 1,002 Mn in Q1-FY26 (Page 32). Key concall takeaways from Beta Drugs Ltd's Q1 FY27…
- Fermenta Biotech Ltd (Q1 FY27)
Q1FY27 total revenue: INR 126.2 crore, down 13% YoY (Page 8) . Key concall takeaways from Fermenta Biotech Ltd's Q1 FY27 earnings call — and how it ranks…
Frequently Asked Questions
What were Sanjivani Paranteral Ltd Q1 FY27 results?
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Q1 FY27 Consolidated EBITDA: ₹43.21 Mn, up 61.04% YoY from ₹26.83 Mn - Q1 FY27 EBITDA margin: 18.01% (0.18 on total income), improvement from 15% in Q1 FY26 - Q1 FY27 Consolidated Profit After Tax
What is Sanjivani Paranteral Ltd share price analysis?
Sanjivani Paranteral Ltd currently shows a neutral. The stock trades at a P/E of 27.0 with a market cap of ₹203 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sanjivani Paranteral Ltd planning capital expenditure?
Pune IV-fluid infusion plant: - Commercial production started Dec 2025 - Installed capacity: 60 million bottles/year - Revenue ₹35 Mn in FY26 (~2 Mn bottles) - Utilisation ramp guided
Keep Sanjivani Paranteral Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.